Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma.


Journal

Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914

Informations de publication

Date de publication:
01 01 2022
Historique:
received: 23 03 2021
accepted: 24 08 2021
entrez: 4 1 2022
pubmed: 5 1 2022
medline: 24 3 2022
Statut: ppublish

Résumé

Increases in the extent of resection of both contrast-enhanced (CE) and non-contrast-enhanced (NCE) tissue are associated with substantial survival benefits in patients with isocitrate dehydrogenase wild-type glioblastoma. The fact, however, remains that these lesions exist within the framework of complex neural circuitry subserving cognition, movement, and behavior, all of which affect the ultimate survival outcome. The prognostic significance of the interplay between CE and NCE cytoreduction and neurological morbidity is poorly understood. To identify a clinically homogenous population of 228 patients with newly diagnosed isocitrate dehydrogenase wild-type glioblastoma, all of whom underwent maximal safe resection of CE and NCE tissue and adjuvant chemoradiation. We then set out to delineate the competing interactions between resection of CE and NCE tissue and postoperative neurological impairment with respect to overall survival. Nonparametric multivariate models of survival were generated via recursive partitioning to provide a clinically intuitive framework for the prognostication and surgical management of such patients. We demonstrated that the presence of a new postoperative neurological impairment was the key factor in predicting survival outcomes across the entire cohort. Patients older than 60 yr who suffered from at least one new impairment had the worst survival outcome regardless of extent of resection (median of 11.6 mo), whereas those who did not develop a new impairment had the best outcome (median of 28.4 mo) so long as all CE tissue was resected. Our data provide novel evidence for management strategies that prioritize safe and complete resection of CE tissue.

Sections du résumé

BACKGROUND
Increases in the extent of resection of both contrast-enhanced (CE) and non-contrast-enhanced (NCE) tissue are associated with substantial survival benefits in patients with isocitrate dehydrogenase wild-type glioblastoma. The fact, however, remains that these lesions exist within the framework of complex neural circuitry subserving cognition, movement, and behavior, all of which affect the ultimate survival outcome. The prognostic significance of the interplay between CE and NCE cytoreduction and neurological morbidity is poorly understood.
OBJECTIVE
To identify a clinically homogenous population of 228 patients with newly diagnosed isocitrate dehydrogenase wild-type glioblastoma, all of whom underwent maximal safe resection of CE and NCE tissue and adjuvant chemoradiation. We then set out to delineate the competing interactions between resection of CE and NCE tissue and postoperative neurological impairment with respect to overall survival.
METHODS
Nonparametric multivariate models of survival were generated via recursive partitioning to provide a clinically intuitive framework for the prognostication and surgical management of such patients.
RESULTS
We demonstrated that the presence of a new postoperative neurological impairment was the key factor in predicting survival outcomes across the entire cohort. Patients older than 60 yr who suffered from at least one new impairment had the worst survival outcome regardless of extent of resection (median of 11.6 mo), whereas those who did not develop a new impairment had the best outcome (median of 28.4 mo) so long as all CE tissue was resected.
CONCLUSION
Our data provide novel evidence for management strategies that prioritize safe and complete resection of CE tissue.

Identifiants

pubmed: 34982879
doi: 10.1227/NEU.0000000000001753
pii: 00006123-202201000-00014
pmc: PMC9514750
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-130

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS110919
Pays : United States

Informations de copyright

Copyright © Congress of Neurological Surgeons 2021. All rights reserved.

Références

Gritsenko PG, Atlasy N, Dieteren CEJ, et al. p120-catenin-dependent collective brain infiltration by glioma cell networks. Nat Cell Biol. 2020;22(1):97-107.
Venkatesh HS, Morishita W, Geraghty AC, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019;573(7775):539-545.
Eidel O, Burth S, Neumann JO, et al. Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One. 2017;12(1):e0169292.
Li YM, Suki D, Hess K, et al. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg. 2016;124(4):977-988.
Johnson DR, Sawyer AM, Meyers CA, et al. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol. 2012;14(6):808-816.
Hervey-Jumper SL, Li J, Lau D, et al. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. J Neurosurg. 2015;123(2):325-339.
Gogos AJ, Young JS, Morshed RA, et al. Awake glioma surgery: technical evolution and nuances. J Neurooncol. 2020;147(3):515-524.
Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016;130(2):269-282.
Gulati S, Jakola AS, Nerland US, et al. The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg. 2011;76(6):572-579.
Rahman M, Abbatematteo J, Leo EKD, et al. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg. 2016;127(1):123-131.
Jakola AS, Gulati S, Weber C, et al. Postoperative deterioration in health related quality of life as predictor for survival in patients with glioblastoma: a prospective study. PLoS One. 2011;6(12):e28592.
Ahmadipour Y, Kaur M, Pierscianek D, et al. Association of surgical resection, disability, and survival in patients with glioblastoma. J Neurol Surg A Cent Eur Neurosurg. 2019;80(4):262-268.
Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495-503.
Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115-1123.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6(3):227-235.
Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115(1):3-8.
Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
Certo F, Altieri R, Maione M, et al. FLAIRectomy in supramarginal resection of glioblastoma correlates with clinical outcome and survival analysis: a prospective, single institution, case series. Oper Neurosurg. 2021;20(2):151-163.
Yu J, Jung Y, Park J, et al. Intensive rehabilitation therapy following brain tumor surgery: a pilot study of effectiveness and long-term satisfaction. Ann Rehabil Med. 2019;43(2):129-141.
Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med. 2008;358(1):18-27.
Weyer-Jamora C, Brie MS, Luks TL, et al. Postacute cognitive rehabilitation for adult brain tumor patients. Neurosurgery. Published online February 15, 2021. doi:10.1093/neuros/nyaa552.
doi: 10.1093/neuros/nyaa552
De Witt Hamer PC, Klein M, Hervey-Jumper SL, et al. Functional outcomes and health-related quality of life following glioma surgery. Neurosurgery. 2021;88(4):720-732.
Krishna S, Kakaizada S, Almeida N, et al. Central nervous system plasticity influences language and cognitive recovery in adult glioma. Neurosurgery. 2021;89(4):539-548.
Morshed RA, Young JS, Kroliczek AA, et al. A neurosurgeon's guide to cognitive dysfunction in adult glioma. Neurosurgery. 2021;89(1):1-10.
Morshed RA, Young JS, Lee AT, et al. Clinical pearls and methods for intraoperative awake language mapping. Neurosurgery. 2021;89(2):143-153.
Dayani F, Young JS, Bonte A, et al. Safety and outcomes of resection of butterfly glioblastoma. Neurosurg Focus. 2018;44(6):E4.
Burks JD, Bonney PA, Conner AK, et al. A method for safely resecting anterior butterfly gliomas: the surgical anatomy of the default mode network and the relevance of its preservation. J Neurosurg. 2016;126(6):1795-1811.
Forster MT, Behrens M, Lortz I, et al. Benefits of glioma resection in the corpus callosum. Sci Rep. 2020;10(1):16630.

Auteurs

Alexander A Aabedi (AA)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Jacob S Young (JS)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Yalan Zhang (Y)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Simon Ammanuel (S)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Ramin A Morshed (RA)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Cecilia Dalle Ore (C)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Desmond Brown (D)

Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Joanna J Phillips (JJ)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Department of Pathology, University of California, San Francisco, San Francisco, California, USA.

Nancy Ann Oberheim Bush (NA)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Department of Neurology, University of California, San Francisco, San Francisco, California, USA.

Jennie W Taylor (JW)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Department of Neurology, University of California, San Francisco, San Francisco, California, USA.

Nicholas Butowski (N)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Jennifer Clarke (J)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Department of Neurology, University of California, San Francisco, San Francisco, California, USA.

Susan M Chang (SM)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Manish Aghi (M)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Annette M Molinaro (AM)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Mitchel S Berger (MS)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Shawn L Hervey-Jumper (SL)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH